source
- Eli Lilly’s $3.8 B bid for AtaiBeckley signals strong pharma endorsement of psychedelicsEli Lilly has announced a proposed acquisition of AtaiBeckley valued at up to $3.8 billion. Analysts at H.C. Wainwright described the move as the clearest strategic validation to date of psychedeli…
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceAfter the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…